单核细胞趋化蛋白-1、白细胞介素-6和一氧化氮与脑小血管病患者认知功能的相关性

doi:10.20047/j.issn1673-7210.2023.14.18

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (712 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the association between monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), nitric oxide (NO), and cognitive function in patients with cerebrovascular disease (CSVD). Methods A total of 130 patients diagnosed with CSVD in the First Affiliated Hospital of Hebei North University (hereinafter referred to as “our hospital”) from September 2020 to September 2021 with Montreal cognitive assessment (MoCA) score ＜26 points were collected as the observation group. In addition, 80 patients with no abnormal brain imaging and MoCA score ≥26 points in our hospital during the same period were collected as the control group. Serum MCP-1, IL-6, and NO were compared between the two groups, and the influencing factors of CSVD cognitive dysfunction were analyzed. The diagnostic value was analyzed by the receiver operator characteristic curve, and the correlation between MCP-1, IL-6, NO, and the MoCA score of patients was further analyzed. Results The levels of serum MCP-1 and IL-6 in the observation group were higher than those in the control group, and the serum NO and MoCA scores were lower than those in the control group, the differences were statistically significant (P＜0.05). Multivariate analysis showed that serum MCP-1 (OR=1.055, 95%CI: 1.037-1.074), IL-6 (OR=1.659, 95%CI: 1.431-1.923), NO(OR=0.836, 95%CI: 0.785-0.891) level was independent factors of CSVD cognitive dysfunction. The results of receiver operator characteristic curve analysis showed that the area under the curve of serum MCP-1, IL-6, and NO combined to predict CSVD cognitive dysfunction was 0.880 (P＜0.05), the sensitivity was 82.3%, and the specificity was 83.8%. Serum NO level was positively correlated with MoCA scores in patients with CSVD cognitive dysfunction (r＞0, P＜0.05), while serum MCP-1 and IL-6 levels were negatively correlated with it (r＜0, P＜0.05). Conclusion In patients with CSVD cognitive dysfunction, the levels of serum MCP-1 and IL-6 are increased, while the level of NO is decreased, which are correlated with the level of cognitive function. The combined detection of the three indicators is helpful to predict the occurrence of CSVD cognitive dysfunction.

Key words： Cerebral small vessel disease Cognitive function Monocyte chemokine-1 Interleukin-6 Nitric oxide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Chuanfen1　SONG Zhengyu2　ZHANG Xiaoli2　HU Jin2▲

Cite this article:

LIU Chuanfen1　SONG Zhengyu2　ZHANG Xiaoli2　HU Jin2▲. Association of monocyte chemotactic protein-1, interleukin-6, and nitric oxide with cognitive function in patients with cerebrovascular disease[J]. 中国医药导报, 2023, 20(14): 86-89,110.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.14.18 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I14/86

[1] 乔杉杉，张拥波，赵莹莹，等.脑小血管病临床生化标志物研究进展[J]临床和实验医学杂志，2020，19（6）：671-673.
[2] 李譞婷，胡文立.脑小血管病影像学标志物之间关联性研究的进展[J]中华脑血管病杂志（电子版）2021，15（4）：218-221.
[3] Chojdak-?覵ukasiewicz J，Dziadkowiak E，Zimny A，et al. Cerebral small vessel disease：A review [J]. Adv Clin Exp Med，2021，30（3）：349-356.
[4] 杜昕姝，李国忠.脑小血管病治疗与预后[J]中国实用内科杂志，2021，41（7）：571-574.
[5] Ren B，Tan L，Song Y，et al. Cerebral Small Vessel Disease：Neuroimaging Features，Biochemical Markers，Influencing Factors，Pathological Mechanism and Treatment [J]. Front Neurol，2022，13：843953.
[6] Kalaria RN，Sepulveda-Falla D. Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease [J]. Am J Pathol，2021，191（11）：1888-1905.
[7] Zanon Zotin MC，Sveikata L，Viswanathan A，et al. Cerebral small vessel disease and vascular cognitive impairment：from diagnosis to management [J]. Curr Opin Neurol，2021，34（2）：246-257.
[8] Guy R，Volkman R，Wilczynski E，et al. A Novel Rodent Model of Hypertensive Cerebral Small Vessel Disease with White Matter Hyperintensities and Peripheral Oxidative Stress [J]. Int J Mol Sci，2022，23（11）：5915-5931.
[9] Evans LE，Taylor JL，Smith CJ，et al. Cardiovascular comorbidities，inflammation，and cerebral small vessel disease [J]. Cardiovasc Res，2021，117（13）：2575-2588.
[10] Quick S，Moss J，Rajani RM，et al. A Vessel for Change：Endothelial Dysfunction in Cerebral Small Vessel Disease [J]. Trends Neurosci，2021，44（4）：289-305.
[11] Singh S，Anshita D，Ravichandiran V. MCP-1：Function，regulation，and involvement in disease [J]. Int Immunopharmacol，2021，101（Pt B）：107598.
[12] Kang S，Narazaki M，Metwally H，et al. Historical overview of the interleukin-6 family cytokine [J]. Exp Med，2020， 217（5）：e20190347.
[13] Liao FF，Lin G，Chen X，et al. Endothelial Nitric Oxide Synthase-Deficient Mice：A Model of Spontaneous Cerebral Small-Vessel Disease [J]. Am Pathol，2021，191（11）：1932- 1945.
[14] Kang JM，Cho YS，Park S，et al. Montreal cognitive assessment reflects cognitive reserve [J]. BMC Geriatr，2018，18（1）：261.
[15] 胡文立，杨磊，李譞婷，等.中国脑小血管病诊治专家共识2021[J].中国卒中杂志， 2021，16（7）：716-726.
[16] Lyra E，Silva NM，Gon?觭alves RA，et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease [J]. Transl Psychiatry，2021，11（1）：251.
[17] Murakami M，Kamimura D，Hirano T. Pleiotropy and Specificity：Insights from the Interleukin 6 Family of Cytokines [J]. Immunity，2019，50（4）：812-831.
[18] Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1：Moving Upstream To Identify Novel Targets for Atheroprotection [J]. Circ Res，2016，118（1）：145-156.
[19] Lin J，Li G，Xu C，et al. Monocyte Chemotactic Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities [J]. Mediators Inflamm，2020，2020：8812020.
[20] Yang C，Hawkins KE，Dore S，et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke [J]. Am J Physiol Cell Physiol，2019，316（2）：C135- C153.
[21] Tsui A，Davis D. Systemic inflammation and causal risk for Alzheimer’s dementia：Possibilities and limitations of a Mendelian randomization approach [J]. Aging Med（Milton），2018，1（3）：249-253.
[22] Xu Y，Shen YY，Zhang XP，et al. Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer’s disease and amnestic mild cognitive impairment [J]. Eur J Neurol，2020，27（8）：1429-1435.
[23] Porcellini E，Ianni M，Carbone I，et al. Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimer’s disease [J]. Immun Ageing，2013，10（1）：6.
[24] Tewari D，Sah AN，Bawari S，et al. Role of Nitric Oxide in Neurodegeneration：Function，Regulation，and Inhibition [J]. Curr Neuropharmacol，2021，19（2）：114-126.
[25] Luczak A，Madej M，Kasprzyk A，et al. Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases [J]. Oxid Med Cell Longev，2020，2020：1417981.
[26] Prado AF，Batista RIM，Tanus-Santos JE，et al. Matrix Metalloproteinases and Arterial Hypertension：Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations [J]. Biomolecules，2021，11（4）：585.